Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel

Alberto M. Marchevsky, Andras Khoor, Ann E. Walts, Andrew G. Nicholson, Yu Zhi Zhang, Victor Roggli, John Carney, Anja C. Roden, Henry D. Tazelaar, Brandon T. Larsen, Nolwenn LeStang, Lucian R. Chirieac, Sonja Klebe, Ming Sound Tsao, Marc De Perrot, Andrew Pierre, David M. Hwang, Yin P. Hung, Mari Mino-Kenudson, William TravisJennifer Sauter, Mary Beth Beasley, Françoise Galateau-Sallé

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Localized malignant mesotheliomas (LMM) is an uncommon and poorly recognized neoplasm. Its pathologic diagnosis is often surprising in patients with serosal/subserosal based localized tumors that are clinically suspicious for metastatic lesions or primary sarcomas. Once a tumor is diagnosed as “mesothelioma”, LMM is often mistaken for diffuse malignant mesothelioma (DMM). Best currently available evidence about LMM was collected from the literature and cases diagnosed by members of the International Mesothelioma Panel (IMP). One hundred and one (101) LMM have been reported in the English literature. Patients had localized tumors with identical histopathologic features to DMM. Patients ranged in age from 6 to 82 years; 75% were men. Most (82%) of the tumors were intrathoracic. Others presented as intrahepatic, mesenteric, gastric, pancreatic, umbilical, splenic, and abdominal wall lesions. Tumors varied in size from 0.6 to 15 cm. Most patients underwent surgical resection and/or chemotherapy or radiation therapy. Median survival in a subset of patients was 29 months. Seventy two additional LMM from IMP institutions ranged in age from 28 to 95 years; 58.3% were men. Sixty tumors (83.3%) were intrathoracic, others presented in intraabdominal sites. Tumors varied in size from 1.2 to 19 cm. Median survival for 51 cases was 134 months. Best evidence was used to formulate guidelines for the diagnosis of LMM. It is important to distinguish LMM from DMM as their treatment and prognosis is different. A multidisciplinary approach is needed for the diagnosis of LMM as it shows identical histopathology and immunophenotype to DMM.

Original languageEnglish (US)
Pages (from-to)281-296
Number of pages16
JournalModern Pathology
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2020

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel'. Together they form a unique fingerprint.

  • Cite this

    Marchevsky, A. M., Khoor, A., Walts, A. E., Nicholson, A. G., Zhang, Y. Z., Roggli, V., Carney, J., Roden, A. C., Tazelaar, H. D., Larsen, B. T., LeStang, N., Chirieac, L. R., Klebe, S., Tsao, M. S., De Perrot, M., Pierre, A., Hwang, D. M., Hung, Y. P., Mino-Kenudson, M., ... Galateau-Sallé, F. (2020). Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Modern Pathology, 33(2), 281-296. https://doi.org/10.1038/s41379-019-0352-3